Germany-based Transcatheter Technologies has expanded its platform with the introduction of new Tresillo transcatheter mitral valve implantation (TMVI) system.
Tresillo TMVI has been designed for structural heart therapy, and is expected to improve the way of treating mitral valve insufficiency.
Transcatheter Technologies CEO Wolfgang Goetz said: "Per plan, we are expanding our platform technology to comprise a transfemoral and transapical Trinity TAVI system as well as a transfemoral Tresillo mitral valve implantation system.
"These three systems all share the same features. The premounted, valved stent is folded without the need of an outer sheath, thereby enabling precision controlled positioning and also allowing for repositioning if needed. This feature is most certainly unique to Trinity and Tresillo."
According to the company, around 3% of the population older than 60 years is suffering from symptomatic mitral valve regurgitation and may benefit from the new interventional procedure while avoiding open-heart surgery.
The firm’s Trinity aortic valve prostheses and Tresillo mitral valve prosthesis comprises bovine pericardium valve mounted on a self-expanding Nitinol frame, and enable controlled positioning and repositioning.